NASDAQ:GNOMGlobal X Genomics & Biotechnology ETF Stock Price, Forecast & News

$16.37

-0.23 (-1.39 %)

(As of 05/29/2020 04:00 PM ET)

Add

Today's Range

$16.34

Now: $16.37▼

$16.82

50-Day Range

$13.14

MA: $15.02▼

$16.89

52-Week Range

$10.16

Now: $16.37▼

$17.36

Volume18,358 shs

Average Volume17,890 shs

Market Capitalization$34.38 million

P/E RatioN/A

Dividend Yield0.00%

BetaN/A

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Global X Genomics & Biotechnology ETF.

2.5 Community Rank

Outperform Votes
Global X Genomics & Biotechnology ETF has received 166 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Global X Genomics & Biotechnology ETF has received 164 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Global X Genomics & Biotechnology ETF has received 50.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Global X Genomics & Biotechnology ETF and other stocks. Vote “Outperform” if you believe GNOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNOM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Global X Genomics & Biotechnology ETF has a dividend yield of 0.00%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Global X Genomics & Biotechnology ETF does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Global X Genomics & Biotechnology ETF insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

0.50 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry N/A

Sub-IndustryN/A

SectorN/A

Current SymbolNASDAQ:GNOM

Previous Symbol

CUSIPN/A

CIK1361103

Webwww.completegenomics.com

Phone+1-650-9432800

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares2,100,000

Market Cap$34.38 million

Next Earnings DateN/A

OptionableNot Optionable

Receive GNOM News and Ratings via Email

Sign-up to receive the latest news and ratings for GNOM and its competitors with MarketBeat's FREE daily newsletter.

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Frequently Asked Questions

How has Global X Genomics & Biotechnology ETF's stock been impacted by COVID-19 (Coronavirus)?

Global X Genomics & Biotechnology ETF's stock was trading at $12.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GNOM shares have increased by 26.3% and is now trading at $16.3721. View which stocks have been most impacted by Coronavirus.

Has Global X Genomics & Biotechnology ETF been receiving favorable news coverage?

News coverage about GNOM stock has been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Global X Genomics & Biotechnology ETF earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutGlobal X Genomics & Biotechnology ETF.

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Gilead Sciences (GILD), Quest Diagnostics (DGX), Inovio Pharmaceuticals (INO), Sanofi (SNY), Arcturus Therapeutics (ARCT), Cidara Therapeutics (CDTX), Marina Biotech (MRNA), Ocular Therapeutix (OCUL), BioNTech (BNTX) and Dynavax Technologies (DVAX).

What is Global X Genomics & Biotechnology ETF's stock symbol?

Global X Genomics & Biotechnology ETF trades on the NASDAQ under the ticker symbol "GNOM."

Who are Global X Genomics & Biotechnology ETF's major shareholders?

Global X Genomics & Biotechnology ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include UBS Group AG (3.09%) and Advisor Group Holdings Inc. (0.21%).

Which institutional investors are buying Global X Genomics & Biotechnology ETF stock?

GNOM stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, and Advisor Group Holdings Inc..

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Global X Genomics & Biotechnology ETF's stock price today?

One share of GNOM stock can currently be purchased for approximately $16.37.

How big of a company is Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF has a market capitalization of $34.38 million.

What is Global X Genomics & Biotechnology ETF's official website?

The official website for Global X Genomics & Biotechnology ETF is www.completegenomics.com.

How can I contact Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF's mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The company can be reached via phone at +1-650-9432800.

This page was last updated on 5/31/2020 by MarketBeat.com Staff